Designing early detection programs for ovarian cancer.
作者信息
Hartge Patricia
出版信息
J Natl Cancer Inst. 2010 Jan 6;102(1):3-4. doi: 10.1093/jnci/djp450. Epub 2009 Dec 30.
Abstract
摘要
相似文献
1
Designing early detection programs for ovarian cancer.设计卵巢癌早期检测项目。
J Natl Cancer Inst. 2010 Jan 6;102(1):3-4. doi: 10.1093/jnci/djp450. Epub 2009 Dec 30.
2
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.评估选定卵巢癌生物标志物的领先时间：一项巢式病例对照研究。
J Natl Cancer Inst. 2010 Jan 6;102(1):26-38. doi: 10.1093/jnci/djp438. Epub 2009 Dec 30.
3
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.卵巢癌风险状态对血清生物标志物间皮素、人附睾蛋白4（HE4）和癌抗原125（CA125）诊断性能的影响。
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.
4
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.个人特征对卵巢癌高危绝经后健康女性血清CA125、间皮素和HE4水平的影响。
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7. doi: 10.1158/1055-9965.EPI-08-0150.
5
HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.人附睾蛋白4和间皮素：盆腔肿块患者卵巢癌的新型生物标志物。
Asian Pac J Cancer Prev. 2010;11(1):111-6.
6
Development of a multimarker assay for early detection of ovarian cancer.开发一种用于早期检测卵巢癌的多标志物检测方法。
J Clin Oncol. 2010 May 1;28(13):2159-66. doi: 10.1200/JCO.2008.19.2484. Epub 2010 Apr 5.
7
Potential role of HE4 in multimodal screening for epithelial ovarian cancer.HE4 在卵巢上皮性癌多模态筛查中的作用潜力。
J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4. doi: 10.1093/jnci/djr359. Epub 2011 Sep 14.
8
Usefulness of serum HE4 in endometriotic cysts.血清人附睾蛋白4在子宫内膜异位囊肿中的应用价值
Br J Cancer. 2009 Aug 4;101(3):548. doi: 10.1038/sj.bjc.6605119. Epub 2009 Jun 9.
9
A step forward for two-step screening for ovarian cancer.卵巢癌两步筛查向前迈进了一步。
J Clin Oncol. 2010 May 1;28(13):2128-30. doi: 10.1200/JCO.2009.26.6346. Epub 2010 Apr 5.
10
SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.单独使用以及与CA125联合使用和/或彼此联合使用时，SMRP和HE4作为卵巢癌生物标志物的情况。
Adv Exp Med Biol. 2008;622:15-21. doi: 10.1007/978-0-387-68969-2_2.
引用本文的文献
1
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study.基于微小RNA的特征影响卵巢癌的临床进程和生物学行为：一项微小RNA组学研究
Biomark Res. 2021 Jul 13;9(1):57. doi: 10.1186/s40364-021-00289-6.
2
Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.下调的长非编码 RNA DGCR5 作为卵巢癌诊断和预后的新型有前途的生物标志物。
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819896809. doi: 10.1177/1533033819896809.
3
Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma.抑制RNA结合蛋白Musashi-1可抑制卵巢癌的恶性特性并逆转紫杉醇耐药性。
J Cancer. 2019 Feb 26;10(6):1580-1592. doi: 10.7150/jca.27352. eCollection 2019.
4
Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression.Musashi-1表达是卵巢腺癌的一个预后因素，且与ALDH-1表达相关。
Pathol Oncol Res. 2015 Sep;21(4):1133-40. doi: 10.1007/s12253-015-9943-6. Epub 2015 May 14.
5
Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.用于恶性间皮瘤早期检测的生物标志物：诊断和治疗应用。
Cancers (Basel). 2010 Apr 14;2(2):523-48. doi: 10.3390/cancers2020523.
6
Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.MUC1 适体-miR-29b 嵌合体通过调控 PTEN 甲基化在卵巢上皮性癌细胞中的抑癌作用。
Target Oncol. 2012 Dec;7(4):217-25. doi: 10.1007/s11523-012-0236-7. Epub 2012 Nov 20.
7
Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX.通过卵巢癌细胞 SELEX 筛选的适体的分子识别研究。
PLoS One. 2010 Nov 1;5(11):e13770. doi: 10.1371/journal.pone.0013770.
本文引用的文献
1
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.评估选定卵巢癌生物标志物的领先时间：一项巢式病例对照研究。
J Natl Cancer Inst. 2010 Jan 6;102(1):26-38. doi: 10.1093/jnci/djp438. Epub 2009 Dec 30.
2
Results from four rounds of ovarian cancer screening in a randomized trial.一项随机试验中四轮卵巢癌筛查的结果。
Obstet Gynecol. 2009 Apr;113(4):775-782. doi: 10.1097/AOG.0b013e31819cda77.
3
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).多模式及超声筛查卵巢癌的敏感性和特异性，以及所检测癌症的分期分布：英国卵巢癌筛查协作试验（UKCTOCS）患病率筛查结果
Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.
4
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.用于分类或预测的生物标志物准确性的关键评估：研究设计标准
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8. doi: 10.1093/jnci/djn326. Epub 2008 Oct 7.
Zotero 插件